A brand new research from the College of California San Diego means that glucagon-like peptide-1 (GLP-1) receptor agonists, a category of medicines initially developed for kind 2 diabetes, might have advantages that stretch far past blood sugar and weight administration. These medication, which embody semaglutide (offered as Ozempic and Wegovy) and tirzepatide (generally known as Mounjaro), are already well-known for serving to folks drop pounds and handle metabolic circumstances. Now, researchers have found that they could even be linked to higher survival outcomes in colon most cancers sufferers.
The research analyzed medical information from greater than 6,800 folks recognized with colon most cancers throughout College of California Well being amenities. Sufferers who have been taking GLP-1 drugs have been lower than half as prone to die inside 5 years in comparison with these not utilizing the medication (15.5% versus 37.1%). This putting distinction factors to a doubtlessly highly effective new use for medication which can be already reworking diabetes and weight problems remedy.
The analysis was led by Raphael Cuomo, Ph.D., an affiliate professor within the Division of Anesthesiology at UC San Diego College of Medication and a member of the UC San Diego Moores Most cancers Heart. His crew used the College of California Well being Information Warehouse to evaluation outcomes throughout the state’s educational medical facilities.
After accounting for vital components reminiscent of age, physique mass index (BMI), most cancers severity, and different well being circumstances, the crew discovered that folks taking GLP-1 medication nonetheless had a considerably decrease danger of loss of life. This consistency suggests the protecting good thing about GLP-1 remedy could also be unbiased of different medical or way of life variables.
Why GLP-1 Medication May Defend In opposition to Most cancers
The profit appeared strongest in sufferers with weight problems (BMI over 35). This discovering hints that GLP-1 medication might assist offset a few of the irritation and metabolic stress that may make most cancers tougher to deal with.
Scientists are exploring a number of attainable explanations for this impact. GLP-1 receptor agonists are identified to decrease irritation all through the physique, improve insulin sensitivity, and promote weight reduction — all components that may affect most cancers progress and development. Experimental research in laboratories additionally point out that GLP-1 medication might straight inhibit the expansion of tumor cells, encourage most cancers cell loss of life, and alter the encircling surroundings inside tumors to make them much less supportive of illness unfold.
Nonetheless, researchers warning that it’s nonetheless unclear whether or not the decrease loss of life fee seen on this research displays a direct anti-cancer motion or an oblique results of improved total metabolic well being.
Subsequent Steps: Medical Trials Wanted
Dr. Cuomo emphasised that the findings are observational, that means they don’t but show that GLP-1 medication straight enhance most cancers outcomes. These outcomes spotlight an pressing want for medical trials to check whether or not GLP-1 drugs can truly improve most cancers survival, notably amongst sufferers with obesity-related cancers.
The research was printed in Most cancers Investigation on November 11, 2025.
